About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Invivyd

< Previous 1 2 3 4 Next >
News headline image
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd to Participate in Upcoming Investor Conferences
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd to Participate in Upcoming Investor Conferences
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Appoints William Duke as Chief Financial Officer
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Announces Appointment of Sara Cotter to Board Of Directors
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd to Participate at the Jefferies Healthcare Conference
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Reports First Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd to Participate at H.C. Wainwright’s BioConnect Investor Conference
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Doses First Participants in Phase 1 Trial of VYD222, a Novel Monoclonal Antibody Candidate for COVID-19
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Reports Full Year 2022 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd to Host Conference Call Discussing Full Year 2022 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Optimizes Development Efficiency with Election of VYD222 for Near-Term Clinical Advancement to Address Urgent Unmet Need for COVID-19 Monoclonal Antibodies
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd to Participate at Cowen’s 43rd Annual Healthcare Conference
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Announces Changes to Executive Team
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop
From Invivyd
Via GlobeNewswire
Tickers ADGI IVVD
News headline image
Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer
From Invivyd
Via GlobeNewswire
Tickers ADGI IVVD
News headline image
Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference
From Invivyd
Via GlobeNewswire
Tickers IVVD
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.